The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Open accessAbstract
Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition. U-100592 (S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]- phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide and U-100766 (S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]- 2-oxo-5-oxazolidinyl]methyl]-acetamide are novel oxazolidinone analogs from a directed chemical modification program. MICs were determined for a variety of bacterial clinical isolates; the respective MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 micrograms/ml; methicillin-resistant S. aureus, 4 and 4 micrograms/ml; methicillin-susceptible Staphylococcus epidermidis, 2 and 2 micrograms/ml; methicillin-resistant S. epidermidis, 1 and 2 micrograms/ml; Enterococcus faecalis, 2 and 4 micrograms/ml; Enterococcus faecium, 2 and 4 micrograms/ml; Streptococcus pyogenes, 1 and 2 micrograms/ml; Streptococcus pneumoniae, 0.50 and 1 microgram/ml; Corynebacterium spp., 0.50 and 0.50 micrograms/ml; Moraxella catarrhalis, 4 and 4 micrograms/ml; Listeria monocytogenes, 8 and 2 micrograms/ml; and Bacteroides fragilis, 16 and 4 micrograms/ml. Most strains of Mycobacterium tuberculosis and the gram-positive anaerobes were inhibited in the range of 0.50 to 2 micrograms/ml. Enterococcal strains resistant to vancomycin (VanA, VanB, and VanC resistance phenotypes), pneumococcal strains resistant to penicillin, and M. tuberculosis strains resistant to common antitubercular agents (isoniazid, streptomycin, rifampin, ethionamide, and ethambutol) were not cross-resistant to the oxazolidinones. The presence of 10, 20, and 40% pooled human serum did not affect the antibacterial activities of the oxazolidinones. Time-kill studies demonstrated a bacteriostatic effect of the analogs against staphylococci and enterococci but a bactericidal effect against streptococci. The spontaneous mutation frequencies of S. aureus ATCC 29213 were <3.8 x 10(-10) and <8 x 10(-11) for U-100592 and U-100766, respectively. Serial transfer of three staphylococcal and two enterococcal strains on drug gradient plates produced no evidence of rapid resistance development. Thus, these new oxazolidinone analogs demonstrated in vitro antibacterial activities against a variety of clinically important human pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis
Eustice, D. C., Feldman, P., Zajac, I., & Slee, A. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.8.1218 · Cited by 118
Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall
Krogstad, D. J., & Pargwette, A. R. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.6.965 · Cited by 100
Ashtekar, D. R., Costa-Periera, R., Shrinivasan, T., Iyyer, R., Vishvanathan, N., & RITTEL, W. (1991) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(91)90002-w · Cited by 74
Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound
Daly, J. S., Eliopoulos, G. M., Willey, S., & Moellering, R. C. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.9.1341 · Cited by 71
Stratton, C. W., Liu, C., Ratner, H. B., & Weeks, L. S. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1014 · Cited by 44
Cited by
Pankey, G. A., & Sabath, L. D. (2004) · Clinical Infectious Diseases · doi:10.1086/381972 · Cited by 1,201
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201964 · Cited by 560
The Oxazolidinone Linezolid Inhibits Initiation of Protein Synthesis in Bacteria
Swaney, S. M., Aoki, H., Ganoza, M. C., & Shinabarger, D. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.12.3251 · Cited by 555
Oxazolidinone Structure–Activity Relationships Leading to Linezolid
Barbachyn, M. R., & Ford, C. W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200528 · Cited by 553
Self-citationStevens, D. L., Herr, D., Lampiris, H., Hunt, J. L., Batts, D. H., Hafkin, B., & the Linezolid MRSA Study Group (2002) · Clinical Infectious Diseases · doi:10.1086/340353 · Cited by 506
Linezolid: The First Oxazolidinone Antimicrobial
Moellering, R. C. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00015 · Cited by 455
Hematologic Effects of Linezolid: Summary of Clinical Experience
Gerson, S. L., Kaplan, S. L., Bruss, J. B., Le, V., Arellano, F. M., Hafkin, B., & Kuter, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2723-2726.2002 · Cited by 443
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
French, G. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl393 · Cited by 441
Rubinstein, E., Cammarata, S. K., Oliphant, T. H., Wunderink, R. G., & the Linezolid Nosocomial Pneumonia Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/318486 · Cited by 440
THE MAGIC BULLETS AND TUBERCULOSIS DRUG TARGETS
Zhang, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.100120 · Cited by 432
Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003) · Clinical Infectious Diseases · doi:10.1086/345744 · Cited by 428
Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions
Shinabarger, D. L., Marotti, K. R., Murray, R. W., Lin, A. H., Melchior, E. P., Swaney, S. M., Dunyak, D. S., Demyan, W. F., & Buysse, J. M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2132 · Cited by 384
Diekema, D. J., & Jones, R. N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06964-1 · Cited by 378
Resistance to Linezolid Caused by Modifications at Its Binding Site on the Ribosome
Long, K. S., & Vester, B. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05702-11 · Cited by 375
Linezolid: The First Oxazolidinone Antimicrobial
Paterson, D. L., Pasculle, A. W., & McCurry, K. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00017 · Cited by 328
Lipsky, B. A., Itani, K., Norden, C., & the Linezolid Diabetic Foot Infections Study Group (2004) · Clinical Infectious Diseases · doi:10.1086/380449 · Cited by 311
Antimicrobial Resistance to Linezolid
Meka, V. G., & Gold, H. S. (2004) · Clinical Infectious Diseases · doi:10.1086/423841 · Cited by 309
Prystowsky, J., Siddiqui, F., Chosay, J., Shinabarger, D. L., Millichap, J., Peterson, L. R., & Noskin, G. A. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.7.2154-2156.2001 · Cited by 302
Prediction of antibiotic resistance: time for a new preclinical paradigm?
Sommer, M. O. A., Munck, C., Toft-Kehler, R. V., & Andersson, D. I. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.75 · Cited by 301
Emergence and management of drug-resistant enterococcal infections
Arias, C. A., & Murray, B. E. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.5.637 · Cited by 294
Morales, G., Picazo, J. J., Baos, E., Candel, F. J., Arribi, A., Peláez, B., Andrade, R., de la Torre, M., Fereres, J., & Sánchez‐García, M. (2010) · Clinical Infectious Diseases · doi:10.1086/650574 · Cited by 292
Linezolid: A Review of its Use in the Management of Serious Gram-Positive Infections
Perry, C. M., & Jarvis, B. (2001) · Drugs · doi:10.2165/00003495-200161040-00008 · Cited by 275
Linezolid in vitro: mechanism and antibacterial spectrum
Livermore, D. M. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg249 · Cited by 269
The oxazolidinones: past, present, and future
Shaw, K. J., & Barbachyn, M. R. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06330.x · Cited by 259
Self-citationDrugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis
Sacchettini, J. C., Rubin, E. J., & Freundlich, J. S. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1816 · Cited by 256
Mendes, R. E., Deshpande, L. M., & Jones, R. N. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.04.002 · Cited by 221
Jacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., & Caillon, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.1.45-51.2005 · Cited by 95
Metadata
- Authors
- Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1996-04
- Volume
- 40
- Issue
- 4
- Pages
- 839-845
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2151859311
- Cited by
- 461
- References
- 6
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.